Work Here?
Overview
Elegen provides custom DNA synthesis services for researchers, biotech firms, and pharmaceutical companies, focusing on DNA manufacturing with fast turnaround and high accuracy. Clients submit DNA designs and Elegen’s synthesis platform produces the requested sequences with precise fidelity. Its differentiators include speed and precision, support for producing small molecules, biologics, antibodies, and cytokines, and an Early Access Program for early DNA breakthroughs. The goal is to accelerate the bioeconomy by speeding DNA manufacturing to enable faster development of mRNA medicines and other advanced therapeutics.
About Elegen
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$35M
Headquarters
San Carlos, California
Founded
2017
Get referred to Elegen
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 15, 2025 Nutcracker pilot targets cell-free RNA therapeutics manufacturing.
- April 1, 2025 IDT partnership exposes ENFINIA Plasmid DNA to more buyers.
- September 9, 2025 IVT Ready DNA speeds mRNA workflows and broadens clinical demand.
What critics are saying
- January 27, 2026 price cuts to $0.07 per base crush margins.
- IDT and competitors can bundle long-DNA offerings and commoditize Elegen’s premium position.
- If ENFINIA pilots stall, customers revert to plasmid workflows and Elegen loses its wedge.
What makes Elegen unique
- Elegen’s GEN II platform combines microfluidics, AI, and cell-free cloning.
- ENFINIA ships NGS-verified, high-complexity DNA in 6-10 business days.
- It accepts sequences rejected by competitors, including ITRs, repeats, and long homopolymers.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$35M
Meets
Industry Average
Funded Over
1 Rounds
Andreessen HorowitzIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Short Term Disability
Long Term Disability
Parental Leave
Commuter Benefits
Fitness Allowance
Learning Allowance
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 11%Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot program to demonstrate the industry's first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer therapeutics (PCTs).
Elegen, the leader in next-generation cell-free DNA manufacturing, announced the early access launch of ENFINIA IVT Ready DNA.
IDT lengthens DNA offerings with Elegen partnership.
Elegen, a San Carlos, CA-based DNA synthesis company, raised $35M in Series B funding led by Triatomic Capital, with participation from GSK, John Ballantyne, and existing investors including Andreessen Horowitz. Peter Zhou of Triatomic Capital will join Elegen’s board. The funds will be used to expand the ENFINIA™ DNA product line for clinical development of genetic medicines. CEO Matthew Hill aims to accelerate DNA synthesis and streamline new clinical modalities.
Elegen, a San Carlos, CA-based company which specialises in DNA synthesis and production, raised $35M in Series B funding.
There are no jobs for Elegen right now.
Find jobs on Simplify and start your career today
About Elegen
Industries
Industrial & Manufacturing
Biotechnology
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$35M
Headquarters
San Carlos, California
Founded
2017
There are no jobs for Elegen right now.
Find jobs on Simplify and start your career today